Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774175 | 0.87 | HPGD (0.37) | MEN1KMT2ALMNAGAAKDM4E | |
| SCHEMBL1551480 | 0.84 | L3MBTL1 (0.44) | L3MBTL1TP53MEN1KMT2ALMNA | |
| SCHEMBL1551492 | 0.82 | L3MBTL1 (0.43) | L3MBTL1TP53MEN1KMT2ALMNA | |
| SCHEMBL1551486 | 0.79 | MAPT (0.36) | TP53MEN1KMT2ALMNANPSR1 | |
| SCHEMBL1552563 | 0.78 | ALDH1A1 (0.36) | MEN1KMT2ALMNAGAAKDM4E | |
| SCHEMBL2157006 | 0.78 | LMNA (0.45) | L3MBTL1TP53MEN1KMT2ALMNA | |
| SCHEMBL1551484 | 0.73 | CHRM3 (0.40) | GAAKDM4EHTTMAPTHPGD | |
| SCHEMBL1552744 | 0.71 | HPGD (0.39) | L3MBTL1LMNAGAANPSR1KDM4E | |
| SCHEMBL1552074 | 0.71 | SMN1; SMN2 (0.39) | MEN1KMT2ALMNANPSR1KDM4E | |
| SCHEMBL3770444 | 0.70 | CHRM3 (0.40) | TP53MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891035-B1 | SUBSTITUTED BENZO-CONDENSED CYCLOHEPTANONE DERIVATIVES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2011-04-27 | — | — | EP | claimed |
| US-7858613-B2 | Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-12-28 | — | — | US | claimed |
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| US-7858613-B2 | Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | ABCB1, DHFR, DHPS | L3MBTL1 4718/4885TP53 4130/4885MEN1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.